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Abstract Interleukin-6 (IL-6) is a multifunctional cytokine that
plays important roles in the immune system, hematopoiesis, and
acute phase reactions. Transforming growth factor-L (TGF-L)
also has pleiotropy including the production of acute phase
proteins in hepatocytes. To elucidate the cross-talk between IL-6
and TGF-L signaling pathways in hepatic cells, we investigated
the effects of TGF-L on IL-6-induced signal transducer and
activator of transcription-3 (STAT3) activation in a human
hepatoma cell line, Hep3B. IL-6-induced activation of STAT3
activity and STAT3-mediated gene expression were augmented
by TGF-L in Hep3B cells. We provide evidence that these
activities were due to physical interactions between STAT3
and Sma- and MAD-related protein-3, bridged by p300. These
results demonstrate a molecular mechanism of a cross-talk
between STAT3 and TGF-L signaling pathways in hepato-
cytes. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates
immune and in£ammatory responses [1,2]. The receptors for
the IL-6 family of cytokines share the gp130 molecule through
which signals are generated, although the cytoplasmic region
of gp130 does not contain any catalytic domain. Instead, the
Janus kinase (Jak) family of protein kinases constitutively
associate with gp130 and are activated by the IL-6 family of
cytokines [3], leading to the tyrosine phosphorylation and
activation of the signal transducer and activator of transcrip-
tion (STAT) family of transcription factors.
One member of the STAT family of proteins is STAT3
which is mainly activated by the IL-6 family of cytokines,
epidermal growth factor, and leptin [2,3]. Like other members
of the STAT family, STAT3 is tyrosine-phosphorylated by
Jak kinases, upon which it dimerizes, and translocates into
the nucleus to activate target genes [4,5].
The members of the Smad (Sma- and MAD-related protein)
family are signal transducers of the transforming growth fac-
tor-L (TGF-L) superfamily. Smad2 and Smad3 transduce sig-
nals for TGF-L. Smad4 acts as a common partner for these
Smad proteins. When TGF-L receptors are activated by the
binding of cognate ligands, Smads are phosphorylated by the
type I receptor (TLR-I) serine-threonine kinases. Phosphory-
lated Smads form stable complexes with Smad4, and these
complexes translocate into the nucleus where they activate
transcription as a coactivator of DNA-binding transcription
factors. Smad7, one of the inhibitory Smads, also stably in-
teracts with activated TLR-I and inhibits the TGF-L signal
[6,7].
IL-6 has been shown to be the principal regulator of most
acute phase proteins [2,8] although other in£ammation-asso-
ciated cytokines also contribute to this process. IL-1 and tu-
mor necrosis factor-K have been found to participate in in-
duction of a broad subset of acute phase proteins, and both
TGF-L and interferon-Q can induce limited subsets of acute
phase proteins [9]. TGF-L has also been shown to have an
e¡ect on IL-6-regulated acute phase proteins [10^12]. IL-6 has
been shown to activate members of the CCAAT/enhancer
binding protein (C/EBP) family of transcription factors in
hepatoma cell lines [13]. It has recently been found that
STAT3 may also play a major role in mediating IL-6 e¡ects
in hepatocytes [3^5].
Recently, an IL-6 family cytokine, leukemia inhibitory fac-
tor (LIF), and a TGF-L family cytokine, bone morphogenetic
protein-2 (BMP-2), were shown to act in synergy on primary
fetal neural progenitor cells to induce astrocytes [14]. It was
also demonstrated that the formation of a complex between
STAT3 and Smad1, bridged by p300, is involved in the coop-
erative signaling of LIF and BMP-2 and the subsequent in-
duction of astrocytes from neural progenitors.
In this study, we showed that IL-6-induced gene expression
in hepatoma cells was enhanced by TGF-L signal and the
cross-talk between the IL-6 and TGF-L signaling cascades
occurs by physical and functional interactions between
STAT3 and Smad3, bridged by p300 in a hepatoma cell line.
2. Materials and methods
2.1. Reagents and antibodies
Human recombinant IL-6 was a kind gift from Ajinomoto (Tokyo,
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Japan). Human recombinant TGF-L1 was purchased from Strath-
mann Biotech GmbH (Germany). Human recombinant LIF was
purchased from Intergen (Purchase, NY, USA). Expression vec-
tors, Smad2, Smad3, Smad4, Smad7, Smad3DE, 6UMyc-tagged
Smad3, and Flag-tagged p300 were described previously [15]. Flag-
tagged STAT3-C [16], wild-type TLR-I, TLR-I (T204D), p3TP-
LUC [17], C/EBPN [18], a dominant-negative form of STAT3
(DN-STAT3) [19], and STAT3-LUC [20] were kindly provided by
Dr. J.F. Bromberg (Rockefeller University, New York, NY, USA),
Dr. J. Massague (Memorial Sloan-Kettering Cancer Center, New
York, NY, USA), Dr. S. Akira (Osaka University, Osaka, Japan)
and Dr. T. Hirano (Osaka University, Osaka, Japan), respectively.
Anti-HA, anti-Myc, anti-STAT3, anti-Smad3, anti-p300 antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-phospho-STAT3 (Ser727) was purchased from Cell
Signaling Technology (Beverly, MA, USA). Anti-Flag M2 anti-
body was purchased from Upstate Biotechnology (Lake Placid, NY,
USA).
2.2. Cell culture, transfections, and luciferase assays
The human hepatoma cell line Hep3B was maintained in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS). Before stimulation, the cells were cultured for 24 h in
DMEM without FCS, followed by treatment with IL-6 and/or TGF-
L1. Hep3B cells (2^2.5U105 in a 6-cm dish) were transfected using
FuGENE6 (Roche Molecular Biochemicals) following the manufac-
Fig. 1. TGF-L potentiates IL-6-induced STAT3 activation. A: Hep3B cells were transfected with STAT3-LUC reporter (1 Wg). 48 h after trans-
fection, cells were stimulated with various concentrations of IL-6 and/or TGF-L1 and cells were harvested and relative luciferase activities were
measured. The results are presented as fold induction of luciferase activity from triplicate experiments. The error bars represent the standard
deviations. B: E¡ect of IL-6 and/or TGF-L on C/EBPN expression in Hep3B cells. 20 Wg of total RNA from Hep3B cells treated with IL-6
(100 ng/ml) and/or TGF-L1 (30 ng/ml) for 1, 3, or 6 h was used for Northern blot analysis. The fold induction of C/EBPN expression is shown
as the densitometric intensity. Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA is included as a loading control (lower panel).
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turer’s instructions. 293T cells were maintained in DMEM containing
10% FCS and transfected in DMEM containing 1% FCS by the stan-
dard calcium precipitation protocol. Luciferase assay was performed
as described [21]. The cells were harvested 48 h after transfection and
lysed in 100 Wl of PicaGene Reporter Lysis Bu¡er (Toyo Ink, Tokyo,
Japan) and assayed for luciferase and L-galactosidase activities ac-
cording to the manufacturer’s instructions. Luciferase activities were
normalized to the L-galactosidase activities. Three or more independ-
ent experiments were carried out.
2.3. Northern blot analysis
Hep3B cells were maintained as described above. After serum star-
vation, cells (1U107) were treated with IL-6 (100 ng/ml) and/or TGF-
L1 (30 ng/ml) for 1, 3, or 6 h. Total RNAs were prepared using Iso-
Gen (Nippon Gene) and used in Northern analysis according to es-
tablished procedures. A nylon membrane (Hybond N, Amersham
Pharmacia Biotech) and radiolabelled cDNA probes, as indicated,
were used.
2.4. Immunoprecipitation and immunoblotting
The immunoprecipitation and Western blotting were performed as
described previously [22]. 293T cells were harvested and lysed in lysis
bu¡er (50 mM Tris^HCl, pH 7.4, 0.15 M NaCl, containing 0.5% NP-
40, 1 WM sodium orthovanadate, 1 WM phenylmethylsulfonyl £uoride,
and 10 Wg/ml each of aprotinin, pepstatin, and leupeptin). Hep3B cells
were stimulated with IL-6 (100 ng/ml) and/or TGF-L1 (100 ng/ml) for
15 min. Nuclear extracts were prepared as described previously [23].
Nuclear extracts in the above lysis bu¡er were immunoprecipitated
with anti-p300 antibody. The immunoprecipitates from cell lysates
were resolved on 5^20% SDS^PAGE and transferred to Immobilon
¢lters (Millipore, Bedford, MA, USA). The ¢lters were then immuno-
blotted with each antibody. Immunoreactive proteins were visualized
using an enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech).
3. Results and discussion
3.1. TGF-L potentiates IL-6-induced STAT3 activation
To examine the molecular basis of the cross-talk between
IL-6 and TGF-L signaling pathways, we utilized an IL-6-re-
sponsive human hepatoma cell line, Hep3B, and the transient
transfection assay. The STAT3-mediated transcriptional re-
sponses were measured using STAT3-LUC, in which the K2-
macroglobulin promoter [20] drives expression of the lucifer-
ase (LUC) reporter gene. Hep3B cells were transfected with
STAT3-LUC and treated with IL-6 and/or TGF-L and LUC
activities were determined. As shown in Fig. 1A, IL-6 stimu-
lated STAT3-LUC activity in a dose-dependent manner,
whereas TGF-L alone did not have an e¡ect. When cells
were treated with both IL-6 and TGF-L1, STAT3-LUC activ-
ity increased two-fold compared with the activation by IL-6
alone.
To further examine whether TGF-L has any e¡ects on IL-6-
induced transcriptional activation of cellular genes, we carried
out Northern analysis on RNA samples prepared from Hep3B
cells which had been stimulated with IL-6 and/or TGF-L. As a
cellular target for IL-6/STAT3, we analyzed the expression of
C/EBPN which is a regulator of acute phase response genes in
hepatocytes and is upregulated by IL-6 treatment [18]. As
shown in Fig. 1B, C/EBPN expression was induced at 1 h after
treatment with IL-6 alone in Hep3B cells. This IL-6-induced
C/EBPN expression was markedly enhanced by the addition of
TGF-L, whereas TGF-L alone did not a¡ect C/EBPN expres-
sion. This enhancement was not observed at 3 h after treat-
ment, and suppressed at 6 h after treatment. These data show
that TGF-L potentiates IL-6-induced STAT3-LUC transcrip-
tion activity as well as IL-6-induced early transcription of C/
EBPN in Hep3B cells.
3.2. Reconstitution of the cross-talk between STAT3 and
TGF-L signaling pathways in 293T cells
Previous studies have shown that p300/CBP is involved in
STAT3- or Smad-mediated transcriptional activation [15,24].
Recently, it has been shown that p300 interacts physically
with STAT3 at its amino-terminus, and with Smad1 at its
carboxy-terminus in a ligand-dependent manner. Further-
more, it was demonstrated that the formation of a complex
between STAT3 and Smad1, bridged by p300, is involved in
the cooperative signaling of LIF and BMP-2 in neural pro-
genitor cells [14].
To further delineate the details of the cross-talk between
IL-6 and TGF-L signaling pathways via p300/CBP, we carried
out transient transfection experiments in 293T cells. 293T cells
were transfected with STAT3-LUC, and cells were stimulated
with increasing amounts of LIF. We utilized LIF instead of
IL-6 to activate STAT3-LUC in 293T cells, because LIF
stimulated STAT3-LUC more e¡ectively than IL-6 in these
cells (data not shown). As shown in Fig. 2A, STAT3-LUC
activity was induced by LIF in a dose-dependent manner. As
expected from a previous report [24], additional expression of
p300 augmented LIF-induced STAT3 activation in 293T cells.
To assess whether these e¡ects were mediated through STAT3
or some other intermediary factors, we used DN-STAT3 [19].
As expected, DN-STAT3 signi¢cantly inhibited LIF-induced
STAT3-LUC expression in a dose-dependent fashion (Fig.
2A).
We next assessed the transcriptional activity by TGF-L sig-
nal in 293T cells using p3TP-LUC as reporter gene (Fig. 2B).
293T cells were transfected with p3TP-LUC together with or
without an expression vector for wild-type TLR-I, and cells
were stimulated with increasing amounts of TGF-L. p3TP-
LUC activity was augmented by increasing amounts of
TGF-L1 in 293T cells. When we co-transfected increasing
amounts of the constitutively active form of TLR-I (T204D),
with p3TP-LUC into 293T cells, p3TP-LUC activity increased
in a dose-dependent fashion. TLR-I (T204D) stimulated
p3TP-LUC more e¡ectively than TGF-L/wild-type TLR-I in
these cells. In addition, TLR-I (T204D) did not a¡ect STAT3-
LUC activity.
We then assessed the e¡ect of TGF-L signal on STAT3
activity in 293T cells using TLR-I (T204D). 293T cells were
transfected with increasing amounts of TLR-I (T204D) and
STAT3-LUC in the presence of p300, and cells were stimu-
lated with LIF. As shown in Fig. 2C, TLR-I (T204D) en-
hanced LIF-induced STAT3-LUC activity in a dose-depen-
dent fashion. This enhancement of STAT3 activity by TLR-I
(T204D) was observed in the absence of p300, but it was less
e¡ective compared with that observed in the presence of p300
(data not shown). These results indicate that the enhanced
e¡ect of TGF-L signal on STAT3 transcriptional activity
can be reconstituted in 293T cells similar to those observed
in Hep3B cells.
We next examined whether this e¡ect was due to the Smad
protein family, downstream signal transducers of the TGF-L
superfamily. When either receptor-regulated Smads, Smad2
and Smad3, or a common-partner Smad, Smad4, was ex-
pressed in 293T cells, enhancement of LIF-induced STAT3-
LUC activity by TGF-L signal was increased in a dose-depen-
dent fashion (Fig. 2D). Conversely, no enhancement of LIF-
induced STAT3-LUC activity by TGF-L signal was observed
by expression of Smad7, an inhibitory Smad in 293T cells.
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Furthermore, a dominant-negative form of Smad3,
Smad3DE, also suppressed the enhancement of LIF-induced
STAT3-LUC activity by TGF-L signal (Fig. 2E). These data
suggest that enhancement of STAT3 activation by the TGF-
L1 signal in 293T cells is mediated through the Smad protein
family in the presence of p300.
3.3. TGF-L signal enhances STAT3 activation by an active
form of STAT3
To examine the direct cross-talk between STAT3 and the
TGF-L signal, we used a constitutively active form of STAT3,
STAT3-C [16]. 293T cells were transfected with STAT3-LUC,
expression vectors for STAT3-C and/or increasing amounts of
TLR-I (T204D), and the LUC activity was measured. As
shown in Fig. 3, high STAT3-LUC activity was induced by
STAT3-C, whereas TLR-I (T204D) alone did not show any
e¡ect (data not shown). Expression of TLR-I (T204D) resulted
in enhancement of STAT3-C-induced STAT3-LUC activation
and further expression of Smad3 but not Smad3DE showed
the increase of STAT3-LUC activation. Additional expression
of p300 showed the marked increase of STAT3 activation
induced by STAT3-C with or without TLR-I (T204) and
Smad3. These results clearly show the existence of cross-talk
between the TGF-L signal and STAT3 in 293T cells.
Fig. 2. Reconstitution of the cross-talk between STAT3 and TGF-L signaling pathways in 293T cells. A: 293T cells were transfected with
STAT3-LUC (1 Wg), and/or p300 expression construct (0.1 Wg), and/or various doses (0.1^1.0 Wg) of DN-STAT3. 48 h after transfection, cells
were stimulated for an additional 12 h with LIF (10^100 ng/ml) as indicated and cells were harvested and relative luciferase activities were mea-
sured. B: 293T cells were transfected with p3TP-LUC (1 Wg), and/or wild-type TLR-I (1 Wg), various doses (0.1^1.0 Wg) of TLR-I (T204D) ex-
pression construct. 48 h after transfection, cells were stimulated for an additional 12 h with TGF-L (100 ng/ml) and cells were harvested and
relative luciferase activities were measured. C: 293T cells were transfected with STAT3-LUC (1 Wg), and p300 expression construct (0.1 Wg),
and/or various doses (0.03^1.0 Wg) of TLR-I (T204D). 48 h after transfection, cells were stimulated for an additional 12 h with LIF (30 ng/ml)
and cells were harvested and relative luciferase activities were measured. D: 293T cells were transfected with STAT3-LUC (1 Wg), and p300 ex-
pression construct (0.1 Wg), and/or various doses (0.01^0.5 Wg) of Smad2, Smad3, Smad4, Smad7 as indicated, together with TLR-I (T204D)
(0.1 Wg). 48 h after transfection, cells were stimulated for 12 h with LIF (30 ng/ml) and cells were harvested and relative luciferase activities
were measured. E: 293T cells were transfected with STAT3-LUC (1 Wg), and p300 expression construct (0.1 Wg), and/or various doses (0.01^0.5
Wg) of Smad3DE as indicated, together with TLR-I (T204D) (0.3 Wg). 48 h after transfection, cells were stimulated for 12 h with LIF (30 ng/
ml) and cells were harvested and relative luciferase activities were measured. The results are presented as fold induction of luciferase activity
from triplicate experiments. The error bars represent the standard deviations.
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3.4. STAT3 and Smad3 physically interact via p300 in vivo
One of the mechanisms that are consistent with the data
described above is direct modi¢cation of STAT3 by TLR-I
(T204D), such as phosphorylation of STAT3, which trigger
its activation. Therefore, we assessed changes in tyrosine
phosphorylation of STAT3 in 293T cells. As shown in Fig.
4A, tyrosine phosphorylation of STAT3 did not show any
change by expression of TLR-I (T204D), whereas phosphor-
ylation of STAT3 on Ser727 was enhanced two-fold by the
densitometric intensity. Although it remains unclear how
phosphorylation of STAT3 on Ser727 is linked to transcrip-
tional activation, it has been demonstrated in many cellular
settings that this residue is essential for maximal STAT3 tran-
scriptional activation [25]. In addition, a direct physical inter-
action between STAT3 and TLR-I (T204D) was observed in
293T cells (Fig. 4B). We tested another possibility, whether
there are direct physical interactions between STAT3 and
Smads. Expression vectors encoding 6UMyc-tagged Smad3
and/or HA-tagged STAT3 together with Jak1 were transiently
transfected into 293T cells. However, we could not ¢nd a
direct interaction between STAT3 and Smad3 in 293T cells
(data not shown). A recent study showed that the formation
of a complex between STAT3 and Smad1 bridged by p300 is
involved in the synergistic signaling in fetal brain [14]. There-
fore, we next examined this possibility. We transfected those
expression constructs together with Flag-p300 into 293T cells.
As shown in Fig. 4C, both STAT3 and Smad3 physically
associated with p300. In parallel, similar co-immunoprecipita-
tion experiments were performed using nuclear extracts ob-
tained from Hep3B cells that had been either left untreated
or treated with IL-6 and TGF-L. As shown in Fig. 4D, anti-
p300 immunoprecipitate from Hep3B cells contained both
STAT3 and Smad3 protein. These data indicate that STAT3
and Smad3 physically interact via p300 in vivo.
3.5. Concluding remarks
We have shown here that the TGF-L signal potentiates IL-6
signaling mediated by STAT3 in hepatoma cells and that ac-
tive Smad interacts with STAT3 via p300. TGF-L treatment
augmented endogenous early STAT3-mediated C/EBPN gene
expression in Hep3B cells as well as STAT3-dependent report-
er activity in Hep3B and 293T cells. On the other hand, en-
dogenous late STAT3-mediated C/EBPN gene expression in
Hep3B cells was suppressed by the treatment of TGF-L.
This result coincides with previous data that TGF-L abolishes
expression of several genes expressed in basal conditions in
Hep3B cells and inhibits some IL-6-induced liver genes [11].
The mechanism of this suppressive e¡ect of TGF-L in Hep3B
cells is unclear at the present time and further studies are
required to understand this event.
It is noteworthy that phosphorylation of STAT3 on Ser727
was enhanced by overexpression of TLR-I (T204D) and that a
Fig. 3. TGF-L signal enhances STAT3 activation by an active form of STAT3. 293T cells were transfected with STAT3-LUC (1 Wg) together
with STAT3-C expression construct (1 Wg), and/or various doses (0.03^0.3 Wg) of TLR-I (T204D), Smad3 or Smad3DE, with or without p300
(0.1 Wg). 48 h after transfection, cells were harvested and relative luciferase activities were measured. The results are presented as fold induction
of luciferase activity from triplicate experiments. The error bars represent the standard deviations.
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direct physical interaction between STAT3 and TLR-I
(T204D) was observed in 293T cells. This implies that TLR-
I (T204D) may be a receptor serine kinase for STAT3. How-
ever, no enhancement of phosphorylation of STAT3 on
Ser727 was observed in Hep3B cells after stimulation of
both IL-6 and TGF-L, indicating that overexpression of
TLR-I (T204D) in 293T cells may be responsible for the en-
hancement.
It was reported that the formation of a complex between
STAT3 and Smad1 bridged by p300 is involved in the syner-
gistic signaling in fetal neural cells [14].
In this study, we have demonstrated a similar mechanism
in a hepatoma cell line. The reconstituted system in 293T
cells described here may not be physiological, but may be
a good tool to explain synergistic actions of distinct types
of cytokines in various biological signaling pathways and
Fig. 4. STAT3 and Smad3 physically interact via p300 in vivo. A: 293T cells (1U107) were transfected with Flag-tagged STAT3 (5 Wg) and/or
various doses of TLR-I (T204D), together with Jak1 (1 Wg). 48 h after transfection, cells were lysed, immunoprecipitated with anti-Flag or anti-
HA as indicated. The immunoprecipitate was probed with anti-phosphotyrosine, anti-phospho-STAT3 (Ser727), anti-Flag, or anti-HA antibody
as indicated. B: 293T cells (1U107) were transfected with Flag-tagged STAT3 (5 Wg) and HA-tagged TLR-I (T204D) (10 Wg), together with
Jak1 (1 Wg). 48 h after transfection, cells were lysed, immunoprecipitated with anti-HA. The immunoprecipitate was probed with anti-Flag or
anti-HA antibody as indicated. C: 293T cells (2U107) were transfected with Flag-p300 (10 Wg) with or without HA-tagged STAT3 (5 Wg),
6UMyc-Smad3 (5 Wg), HA-TLR-I (T204D) (1 Wg) together with Jak1 (1 Wg). 48 h after transfection, cells were lysed, immunoprecipitated with
anti-Flag. The immunoprecipitate was probed with anti-HA, anti-Myc, or anti-Flag antibody as indicated. D: Hep3B cells (5U107) were un-
stimulated or stimulated with IL-6 (100 ng/ml) and TGF-L1 (100 ng/ml) for 15 min, and cells were lysed, immunoprecipitated, and immuno-
blotted with anti-STAT3, anti-Samd3, or anti-p300 antibody as indicated.
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thus provide a clue to develop new drugs for IL-6-related
diseases.
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